You are here: Home » 2024 » April » Archives for 11th

ROSEN, A LEADING LAW FIRM, Encourages Innoviz Technologies Ltd. Investors to Secure Counsel Before Important Deadline in Securities Class Action – INVZ, INVZW

NEW YORK, April 11, 2024 (GLOBE NEWSWIRE) —

WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Innoviz Technologies Ltd. (NASDAQ: INVZ, INVZW) between April 21, 2021 and February 28, 2023, both dates inclusive (the “Class Period”), of the important May 14, 2024 lead plaintiff deadline.

SO WHAT: If you purchased Innoviz securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

WHAT TO DO NEXT: To join the Innoviz class action, go to https://rosenlegal.com/submit–form/?case_id=23435 or call Phillip Kim, Esq. toll–free at 866–767–3653 or email case@rosenlegal.com for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than May 14, 2024. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs’ Bar. Many of the firm’s attorneys have been recognized by Lawdragon and Super Lawyers.

DETAILS OF THE CASE: According to the lawsuit, defendants made false and/or misleading statements and/or failed to disclose that: (1) Innoviz had overstated the benefits that Innoviz was likely to derive from its purported contracts, partnerships, and/or collaborations with automotive companies; (2) as a result, Innoviz was unlikely to achieve the level of profitability that defendants had represented to investors; (3) accordingly, Innoviz had overstated its business and/or financial prospects; and (4) as a result, Innoviz’s public statements were materially false and misleading at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.

To join the Innoviz class action, go to https://rosenlegal.com/submit–form/?case_id=23435 or call Phillip Kim, Esq. toll–free at 866–767–3653 or email case@rosenlegal.com for information on the class action.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the–rosen–law–firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

———————————————–

Contact Information:

        Laurence Rosen, Esq.
        Phillip Kim, Esq.
        The Rosen Law Firm, P.A.
        275 Madison Avenue, 40th Floor
        New York, NY 10016
        Tel: (212) 686–1060
        Toll Free: (866) 767–3653
        Fax: (212) 202–3827
        case@rosenlegal.com
        www.rosenlegal.com


GLOBENEWSWIRE (Distribution ID 9088563)

ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages bluebird bio Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – BLUE

NEW YORK, April 11, 2024 (GLOBE NEWSWIRE) —

WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of bluebird bio, Inc. (NASDAQ: BLUE) between April 24, 2023 and December 8, 2023, both dates inclusive (the “Class Period”), of the important May 28, 2024 lead plaintiff deadline.

SO WHAT: If you purchased bluebird common stock during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

WHAT TO DO NEXT: To join the bluebird class action, go to https://rosenlegal.com/submit–form/?case_id=23717 or call Phillip Kim, Esq. toll–free at 866–767–3653 or email case@rosenlegal.com for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than May 28, 2024. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs’ Bar. Many of the firm’s attorneys have been recognized by Lawdragon and Super Lawyers.

DETAILS OF THE CASE: According to the lawsuit, defendants made false and/or misleading statements. Specifically, defendants created the false impression that: (1) bluebird could obtain Federal Drug Administration (“FDA”) approval for lovo–cel, gene therapy for sickle cell patients, without any black box warnings for haematological malignancies; (2) bluebird would be granted a priority review voucher by the FDA and in turn sell it in order to strengthen bluebird’s financial position for the lovo–cel launch; (3) as a result, bluebird had significantly overstated Lyfgenia’s clinical and/or commercial prospects; and (4) therefore, bluebird’s public statements were materially false and misleading at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.

To join the bluebird class action, go to https://rosenlegal.com/submit–form/?case_id=23717 or call Phillip Kim, Esq. toll–free at 866–767–3653 or email case@rosenlegal.com for information on the class action.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the–rosen–law–firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

Contact Information:

        Laurence Rosen, Esq.
        Phillip Kim, Esq.
        The Rosen Law Firm, P.A.
        275 Madison Avenue, 40th Floor
        New York, NY 10016
        Tel: (212) 686–1060
        Toll Free: (866) 767–3653
        Fax: (212) 202–3827
        case@rosenlegal.com
        www.rosenlegal.com


GLOBENEWSWIRE (Distribution ID 9088511)

ADSK LOSS ALERT: ROSEN, NATIONAL TRIAL COUNSEL, Encourages Autodesk, Inc. Investors to Inquire About Securities Class Action Investigation – ADSK

NEW YORK, April 11, 2024 (GLOBE NEWSWIRE) — WHY: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Autodesk, Inc. (NASDAQ: ADSK) resulting from allegations that Autodesk may have issued materially misleading business information to the investing public.

SO WHAT: If you purchased Autodesk securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. The Rosen Law Firm is preparing a class action seeking recovery of investor losses.

WHAT TO DO NEXT: To join the prospective class action, go to https://rosenlegal.com/submit–form/?case_id=24019 or call Phillip Kim, Esq. toll–free at 866–767–3653 or email case@rosenlegal.com for information on the class action.

WHAT IS THIS ABOUT: On April 1, 2024, after the market closed, Autodesk filed with the SEC a late filing notice on Form NT 10–K. The late filing notice stated Autodesk was unable to file its 10–K for the fiscal year ending January 31, 2024 within the prescribed time period.

Further, Autodesk announced “[a]fter the Company’s earnings release on February 29, 2024, information was brought to the attention of management, which promptly informed the Audit Committee (the “Committee”) of the Board of Directors of the Company, that caused the Committee to commence an internal investigation with the assistance of outside counsel and advisors, regarding the Company’s free cash flow and non–GAAP operating margin practices. The Committee is comprised entirely of outside “independent directors” as defined by the Nasdaq Stock Market listing standards. The investigation is ongoing and all parties are working diligently to complete the investigation. The Company has voluntarily contacted the [SEC] to advise it that an internal investigation is ongoing, and the Committee intends to provide additional information to the Commission as the investigation proceeds. The Company needs further time to assist the Committee in its investigation and to review its practices in this regard.”

On this news, Autodesk’s stock fell $10.73 per share, or 4.1%, to close at $248.71 per share on April 2, 2024.

WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs’ Bar. Many of the firm’s attorneys have been recognized by Lawdragon and Super Lawyers.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the–rosen–law–firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

Contact Information:

        Laurence Rosen, Esq.
        Phillip Kim, Esq.
        The Rosen Law Firm, P.A.
        275 Madison Avenue, 40th Floor
        New York, NY 10016
        Tel: (212) 686–1060
        Toll Free: (866) 767–3653
        Fax: (212) 202–3827
        case@rosenlegal.com
        www.rosenlegal.com


GLOBENEWSWIRE (Distribution ID 9088513)

Nyxoah Nomme le Dr Maurits S. Boon, MD, au Poste de Chief Medical Officer

Nyxoah Nomme le Dr Maurits S. Boon, MD, au Poste de Chief Medical Officer

Nyxoah Nomme le Dr Maurits S. Boon, MD, au Poste de Chief Medical Officer

Mont–Saint–Guibert, Belgique – 11 avril 2024, 22h30 CET / 16h30 ET – Nyxoah SA (Euronext Bruxelles/Nasdaq : NYXH) (« Nyxoah » ou la « Société ») opère dans le secteur des technologies médicales et se concentre sur le développement et la commercialisation de solutions innovantes destinées à traiter le Syndrome d’Apnées Obstructives du Sommeil (SAOS). La Société a annoncé aujourd'hui la nomination du Dr Maurits S. Boon, MD, au poste de Chief Medical Officer.

Le Dr Boon rejoint Nyxoah après avoir travaillé à l'Université Thomas Jefferson, où il continuera à travailler à temps partiel en tant que professeur et Vice–Chairman, chargé de l'éducation. Il est doublement certifié en otolaryngologie – chirurgie de la tête et du cou, et en médecine du sommeil. Le Dr Boon est l'un des deux chirurgiens du sommeil du Jefferson Health à avoir été les premiers à utiliser la thérapie de stimulation du nerf hypoglosse (HGNS) et il est internationalement reconnu comme l'un des chirurgiens les plus expérimentés dans la réalisation de procédures HGNS. Il a donné des conférences dans le monde entier sur l'apnée obstructive du sommeil, a publié de nombreux ouvrages et est co–éditeur du premier livre sur la HGNS.

“En tant que médecin universitaire qui a consacré sa carrière professionnelle aux soins des patients souffrant de troubles respiratoires du sommeil, j'ai eu le privilège de participer à l'essai pivot DREAM U.S.. J'ai d'abord été impressionné par les résultats que j'ai observés chez mes patients, puis tout autant par les données qui ont été récemment publiées. C'est pourquoi je suis honoré qu'on m'ait proposé de rejoindre Nyxoah à un moment aussi passionnant. La stimulation bilatérale du nerf hypoglosse avec Genio a un potentiel énorme et je suis ravi de travailler avec leur équipe talentueuse pour avoir un impact significatif sur la vie des patients souffrant d'apnée obstructive du sommeil”, a commenté le Dr Boon.

“Je ne saurais être plus enthousiaste à l'idée que le Dr Boon rejoigne Nyxoah. Il est l'un des pionniers de la stimulation du nerf hypoglosse et sa décision de devenir directeur médical de Nyxoah reflète la capacité de Genio à améliorer la vie des patients souffrant d'AOS “, a commenté Olivier Taelman, directeur général. “Le Dr Boon jouera un rôle essentiel dans la préparation de notre entrée sur le marché américain et dans la réalisation de notre mission, qui est de rendre le sommeil à nouveau simple.”

À propos de Nyxoah
Nyxoah opère dans le secteur des technologies médicales. Elle se concentre sur le développement et la commercialisation de solutions innovantes destinées à traiter le Syndrome d’Apnées Obstructives du Sommeil (SAOS). La principale solution de Nyxoah est le système Genio®, une thérapie de neurostimulation du nerf hypoglosse sans sonde et sans batterie qui a reçu le marquage CE, centrée sur le patient et destinée à traiter le Syndrome d’Apnées Obstructives du Sommeil (SAOS), le trouble respiratoire du sommeil le plus courant au monde. Ce dernier est associé à un risque accru de mortalité et des comorbidités, dont les maladies cardiovasculaires. La visions de Nyxoah est que les patients souffrant de SAOS doivent pouvoir profiter de nuits réparatrices et vivre pleinement leur vie.

Pour plus d'informations, veuillez consulter le site http://www.nyxoah.com/.

Attention – Marquage CE depuis 2019. Dispositif de recherche aux États–Unis. Limité à un usage expérimental aux États–Unis par la loi fédérale américaine.

Déclarations Prospectives
Certaines déclarations, croyances et opinions contenues dans le présent communiqué de presse sont de nature prospective et reflètent les attentes actuelles de la Société ou, le cas échéant, des administrateurs ou de la direction de la Société concernant le système Genio®, les études cliniques prévues et en cours sur le système Genio®, les avantages potentiels du système Genio® ; les objectifs de Nyxoah en ce qui concerne le développement, la voie réglementaire et l'utilisation potentielle du système Genio® ; l'utilité des données cliniques pour l'obtention éventuelle de l'approbation du système Genio® par la FDA ; et les résultats d'exploitation, la situation financière, les liquidités, les performances, les perspectives, la croissance et les stratégies de la société. De par leur nature, les déclarations prévisionnelles impliquent un certain nombre de risques, d'incertitudes, d'hypothèses et d'autres facteurs qui pourraient faire en sorte que les résultats ou événements réels diffèrent matériellement de ceux exprimés ou sous–entendus dans les déclarations prévisionnelles. Ces risques, incertitudes, hypothèses et facteurs pourraient avoir une incidence négative sur les résultats et les effets financiers des plans et des événements décrits dans le présent document. En outre, ces risques et incertitudes comprennent, sans s'y limiter, les risques et incertitudes énoncés dans la section ” Facteurs de risque ” du rapport annuel de la Société sur le formulaire 20–F pour l'exercice clos le 31 décembre 2023, déposé auprès de la Securities and Exchange Commission (” SEC “) le 20 mars 2024, et des rapports ultérieurs que la Société dépose auprès de la SEC. Une multitude de facteurs, y compris, mais sans s'y limiter, les changements dans la demande, la concurrence et la technologie, peuvent faire en sorte que les événements, les performances ou les résultats réels diffèrent de manière significative de tout développement anticipé. Les déclarations prospectives contenues dans le présent communiqué de presse concernant des tendances ou des activités passées ne constituent pas des garanties de performances futures et ne doivent pas être considérées comme une déclaration selon laquelle ces tendances ou activités se poursuivront à l'avenir. En outre, même si les résultats ou développements réels sont conformes aux déclarations prospectives contenues dans le présent communiqué de presse, ces résultats ou développements peuvent ne pas être représentatifs des résultats ou développements des périodes futures. Aucune déclaration ou garantie n'est donnée quant à l'exactitude ou à la sincérité de ces déclarations prospectives. En conséquence, la Société décline expressément toute obligation ou tout engagement de publier des mises à jour ou des révisions des déclarations prospectives contenues dans le présent communiqué de presse à la suite d'un changement des attentes ou d'un changement des événements, conditions, hypothèses ou circonstances sur lesquels ces déclarations prospectives sont basées, sauf si la loi ou la réglementation l'exige expressément. Ni la Société, ni ses conseillers ou représentants, ni aucune de ses filiales, ni les dirigeants ou employés de ces personnes ne garantissent que les hypothèses sous–jacentes à ces énoncés prospectifs sont exemptes d'erreurs et n'acceptent aucune responsabilité quant à l'exactitude future des énoncés prospectifs contenus dans le présent communiqué de presse ou à la survenance réelle des développements prévus. Vous ne devriez pas accorder une confiance excessive aux déclarations prospectives, qui ne sont valables qu'à la date du présent communiqué de presse.

Contact :
Nyxoah
David DeMartino, Chief Strategy Officer
david.demartino@nyxoah.com
+1 310 310 1313

GLOBENEWSWIRE (Distribution ID 1000934233)

Nyxoah Appoints Dr. Maurits S. Boon, MD as Chief Medical Officer

Nyxoah Appoints Dr. Maurits S. Boon, MD as Chief Medical Officer

Mont–Saint–Guibert, Belgium – April 11, 2024, 10:30pm CET / 4:30pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA), today announced the appointment of Dr. Maurits S. Boon, MD as Chief Medical Officer.

Dr. Boon joins Nyxoah from the Thomas Jefferson University, where he will continue part time as a professor and Vice Chairman, Education. He is dual board–certified in otolaryngology – head and neck surgery, as well as sleep medicine. Dr. Boon is one of two sleep surgeons with Jefferson Health to pioneer the use of hypoglossal nerve stimulation therapy (HGNS) and is internationally recognized as one of the most experienced surgeons performing HGNS procedures. He has lectured worldwide on obstructive sleep apnea, has numerous publications and is co–editor of the first book on HGNS.

“As an academic physician who has dedicated my professional career to the care of patients with sleep disordered breathing, I was privileged to participate in the DREAM U.S. pivotal trial. I was initially impressed by the results I saw in my patients and then equally impressed by the data that were recently reported. As such, I am honored to have been offered a position to join Nyxoah at such an exciting time. Bilateral hypoglossal nerve stimulation with Genio has tremendous potential and I am thrilled to work with their talented team to make a meaningful impact on the lives of patients with obstructive sleep apnea,” commented Dr. Boon.

“I could not be more excited to have Dr. Boon join Nyxoah. He is one of the pioneers in hypoglossal nerve stimulation and his decision to become Nyxoah’s Chief Medical Officer reflects Genio’s ability to improve the lives of OSA patients,” commented Olivier Taelman, Chief Executive Officer. “Dr. Boon will play a critical role as we prepare to enter the U.S. market and achieve our mission of making sleep simple again.”

About Nyxoah
Nyxoah is a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA). Nyxoah’s lead solution is the Genio® system, a patient–centered, leadless and battery–free hypoglossal neurostimulation therapy for OSA, the world’s most common sleep disordered breathing condition that is associated with increased mortality risk and cardiovascular comorbidities. Nyxoah is driven by the vision that OSA patients should enjoy restful nights and feel enabled to live their life to its fullest. 

For more information, please visit http://www.nyxoah.com/.

Caution – CE marked since 2019. Investigational device in the United States. Limited by U.S. federal law to investigational use in the United States.

Forward–looking statements
Certain statements, beliefs and opinions in this press release are forward–looking, which reflect the Company's or, as appropriate, the Company directors' or managements' current expectations regarding the Genio® system; planned and ongoing clinical studies of the Genio® system; the potential advantages of the Genio® system; Nyxoah’s goals with respect to the development, regulatory pathway and potential use of the Genio® system; the utility of clinical data in potentially obtaining FDA approval of the Genio® system; and the Company's results of operations, financial condition, liquidity, performance, prospects, growth and strategies. By their nature, forward–looking statements involve a number of risks, uncertainties, assumptions and other factors that could cause actual results or events to differ materially from those expressed or implied by the forward–looking statements. These risks, uncertainties, assumptions and factors could adversely affect the outcome and financial effects of the plans and events described herein. Additionally, these risks and uncertainties include, but are not limited to, the risks and uncertainties set forth in the “Risk Factors” section of the Company’s Annual Report on Form 20–F for the year ended December 31, 2023, filed with the Securities and Exchange Commission (“SEC”) on March 20, 2024, and subsequent reports that the Company files with the SEC. A multitude of factors including, but not limited to, changes in demand, competition and technology, can cause actual events, performance or results to differ significantly from any anticipated development. Forward looking statements contained in this press release regarding past trends or activities are not guarantees of future performance and should not be taken as a representation that such trends or activities will continue in the future. In addition, even if actual results or developments are consistent with the forward–looking statements contained in this press release, those results or developments may not be indicative of results or developments in future periods. No representations and warranties are made as to the accuracy or fairness of such forward–looking statements. As a result, the Company expressly disclaims any obligation or undertaking to release any updates or revisions to any forward–looking statements in this press release as a result of any change in expectations or any change in events, conditions, assumptions or circumstances on which these forward–looking statements are based, except if specifically required to do so by law or regulation. Neither the Company nor its advisers or representatives nor any of its subsidiary undertakings or any such person's officers or employees guarantees that the assumptions underlying such forward–looking statements are free from errors nor does either accept any responsibility for the future accuracy of the forward–looking statements contained in this press release or the actual occurrence of the forecasted developments. You should not place undue reliance on forward–looking statements, which speak only as of the date of this press release.

Contacts:
Nyxoah
David DeMartino, Chief Strategy Officer
david.demartino@nyxoah.com
+1 310 310 1313

Attachment


GLOBENEWSWIRE (Distribution ID 1000934233)

FC Barcelona and EBC Financial Group to Establish Official Foreign Exchange Partnership for the Next 3.5 Years

BARCELONA, April 11, 2024 (GLOBE NEWSWIRE) — FC Barcelona and EBC Financial Group (EBC) are pleased to announce their partnership in the foreign exchange sector across multiple regions for 3.5 years, commencing today. This partnership designates EBC as FC Barcelona’s official Partner in Foreign Exchange, with coverage extending to regions including APAC, LATAM, the Middle East, and Africa.

This partnership marks a significant milestone for EBC, aligning the brand with the respected legacy and global reach of FC Barcelona. Under this exclusive agreement, EBC is granted the unique privilege to engage in specialized business activities within the foreign exchange domain. The partnership encompasses a range of services, including foreign exchange transactions, trading, brokering (including CFDs), and advisory services.

Through this alliance, EBC is set to innovate and inspire, drawing on the club's rich cultural heritage and passionate fanbase to cultivate meaningful engagement and establish a lasting presence in key regions with a brand–new audience, fostering connections with a vibrant, global community that transcend traditional market boundaries. It is also an unparalleled opportunity to bring FC Barcelona closer to its partners, supporters, and Culers in these regions, alongside its global expansion strategy to grow and continue to lead the industry via exploring the right partners in different sectors.

EBC Financial Group, founded in the esteemed financial centre of London, is a comprehensive financial services group renowned for its expertise in online trading, asset management and investment consultation. With offices strategically located in prominent financial centres, such as London, Hong Kong, Tokyo, Sydney, the Cayman Islands, Singapore, Bangkok, Limassol, and more, EBC caters to a diverse clientele of retail, professional and institutional investors worldwide. Known for its institutional–grade trading environment, the group provides tailor–made financial brokerage, trading services, and an extensive array of investment solutions.

A signing event to commemorate this significant milestone between the Club and EBC will be held at the revamped Spotify Camp Nou at a later date.

Statement by Samuel Hertz, APAC Director of Operations at EBC Financial Group and David Barrett, CEO of EBC Financial Group (UK) Ltd:

“Even though EBC is only four years old, we’ve only grown because we demand the best from ourselves and the industry. We’ve delved deep into FC Barcelona’s storied history, learning from their culture of mentorship where the experienced guide the new, and the new inspire the younger, creating a continuum of growth and excellence. This isn’t just a partnership; it's a shared journey towards greatness, embodying a culture where success is not just about winning but about fostering values, nurturing talent, and contributing positively to society. We're inspired by Barca's way of doing things, their culture where veterans nurture newcomers, passing on wisdom and passion. Our choice of FC Barcelona as a partner is deliberate and profound; it's about learning from the best and embedding their ethos of teamwork, respect, and ambition into our DNA,” stated Samuel Hertz, APAC Director of Operations at EBC Financial Group.

David Barrett, CEO of EBC Financial Group (UK) Limited, the UK subsidiary of EBC Financial Group added, “Being able to forge a partnership with such a strong and respected brand as FC Barcelona underlines the groups ambition to always push ourselves to the highest levels of achievement as possible. EBC Financial Group has firms regulated in the UK by the FCA, Australia by ASIC and the Caymans by CIMA – all highly respected global centres in financial markets – this partnership with FC Barcelona underlines our efforts to align and partner with the best in all aspects.”

Statement by Juli Guiu, Marketing Area Vice President at FC Barcelona:

“This partnership coincides with FC Barcelona’s global expansion plan in recent years, I’m sure that this will help the Club open up a wealth of opportunities in the financial sector through these 3.5 years of partnership with the well–renowned EBC Financial Group. With the untapped potentials we see in the Asia Pacific region, as well as the growing economies in South & Central America, Mexico, Africa, and Middle East, we’re excited to build more connections with brands, partners, supporters, and Culers in these regions.”

About EBC Financial Group
Founded in the esteemed financial district of London, EBC Financial Group (EBC) is renowned for its comprehensive suite of services that includes financial brokerage, asset management, and comprehensive investment solutions. With offices strategically located in prominent financial centres, such as London, Sydney, Hong Kong, Tokyo, Singapore, the Cayman Islands, Bangkok, Limassol, and more, EBC caters to a diverse clientele of retail, professional, and institutional investors worldwide.

Recognised by multiple awards, EBC prides itself on adhering to the highest levels of ethical standards and international regulation. EBC Financial Group (UK) Limited is regulated by the UK's Financial Conduct Authority (FCA), EBC Financial Group (Australia) Pty Ltd is regulated by Australia's Securities and Investments Commission (ASIC), and EBC Financial Group (Cayman) Limited is regulated by the Cayman Islands Monetary Authority (CIMA).

At the core of EBC Group are seasoned professionals with over 30 years of profound experience in major financial institutions, having adeptly navigated through significant economic cycles from the Plaza Accord to the 2015 Swiss franc crisis. EBC champions a culture where integrity, respect, and client asset security are paramount, ensuring that every investor engagement is treated with the utmost seriousness it deserves.

https://www.ebc.com/

About FC Barcelona
FC Barcelona was founded in 1899 and is currently owned by its more than 144,000 members. It is considered the finest multi–sports club in the world and has 125 years of history. Although rooted in its city and its country, Catalonia, its outlook is global. It has official offices in cities in three different continents: Barcelona, Hong Kong, and New York.

Barça seeks to change the world through sporting excellence. This also includes the world of knowledge and innovation through the Barça Innovation Hub (BIHUB). The club is also recognised for its commitment to social causes, which it channels through the FC Barcelona Foundation, and for its work to educate children in the positive values of sport. Barça’s growth in recent years has led it to have more than 486 million followers on social networks.

www.fcbarcelona.com

Media Contact:
Douglas Chew
douglas.chew@ebc.com

Photos accompanying this announcement are available at

https://www.globenewswire.com/NewsRoom/AttachmentNg/4b03d2a3–2caa–4e2a–a1cd–aa739ccaf676

https://www.globenewswire.com/NewsRoom/AttachmentNg/b5d1d1b6–ad04–4056–901b–fe69df1eae6b 


GLOBENEWSWIRE (Distribution ID 9088105)

Rwanda: A Ravaged Country That Bounced Back

Credit: UN Photo/Loey Felipe

 
Hate speech is an alarm bell – the louder it rings, the greater the threat of genocide, UN Secretary-General Antonio Guterres said last year as the General Assembly commemorated the International Day of Reflection on the 1994 Genocide against the Tutsi in Rwanda.

By Margee Ensign
BLAGOEVGRAD, Bulgaria, Apr 11 2024 – As we contemplate the clouded futures of Gaza, Ukraine, and other dire conflict zones that get far less coverage, it may be instructive to recall the surprising success story of a ravaged country that bounced back: Rwanda.

Rwanda’s Genocide Against the Tutsi began 30 years ago this week, and a week of national mourning is underway. The death toll was an order of magnitude worse than in Gaza today: between 500,00 and a million Rwandans were slaughtered in less than three months, and mass graves are still being uncovered.

The U.S saw the victims as “casualties of war” and refused to use the word “genocide.” It stood by as the death toll mounted, an unsettling parallel with U.S. statements and actions on Gaza today. In fact, the US blocked efforts to stop the killing. It led a successful bid to remove UN peacekeepers and stopped UN authorization of reinforcements. It seemed to have made a decision to leave Rwandans to their fate.

No one could have predicted what happened in the wake of the genocide. Since 1994, survivors and attackers reconciled. Life expectancy more than doubled. In fact, 98% of Rwanda’s population now has health insurance.

A million Rwandans have been lifted out of poverty. Rwanda now leads the world’s second largest continent in socio-economic development. It ranks highest for ease of doing business and investment.

It also leads Africa in modelling home-grown solutions for seeking justice, fighting poverty, and promoting gender equity and civic participation. Women are now the majority in Parliament.

All this was unimaginable 30 years ago. How did it happen?

Once the killing had stopped, Rwanda found a creative vision and new ways to seek justice and hold its new leaders accountable for post-genocidal progress. The restorative justice approach of Rwanda’s Gacaca courts was one of the world’s most ambitious post-conflict justice and reconciliation programs.

Over a ten-year period, a million suspects were tried in community-based courts. They confronted war crimes while fostering forgiveness and inclusiveness, allowing communities to heal.

Rwanda’s homegrown Imihigo system, based on pre-colonial cultural practices, reformed the formerly highly centralized government using a decentralized, performance-based governance model that delivered services the traumatized population needed.

Local and national leaders are periodically required to demonstrate the progress and the impact of policies. That contributed to verifiable improvements in access to services, human development indicators, and local political participation.

Since the genocide, gender equity has been embedded in Rwanda’s constitution and its education system, transforming politics, economics, and family life. Today Rwandan women are visionary leaders. Half of the President’s cabinet and 61% of Members of Parliament are female. Rwanda has near-universal primary school enrollment – girls included. With its innovative IT education and nationwide digital network coverage, Rwanda has become a model of educational progress.

So, what lessons can we learn from Rwanda about resilience and reconstruction after the convulsions of war and genocide and how they apply to war-ravaged countries today?

First, we can’t repeat the mistakes of 1994. The U.S. and the international community must stand up to stop the slaughter, and make sure food and access to health care are assured.

Once the killing stops, reconciliation is the way to start rebuilding. If reconciling the antagonists in the Middle East seems hopeless or impossible, just look at Rwanda. In 100 days, over a million members of the Tutsi minority group, as well as Twa and Hutu who and stood up against the genocide, were murdered by Hutu militias.

“The dead of Rwanda accumulated at nearly three times the rate of Jewish dead during the Holocaust,” Philip Gourevitch wrote. “It was the most efficient mass killing since the atomic bombings of Hiroshima and Nagasaki.”

Yet even so, the antagonists eventually came together. It required extraordinary political will, and belief in the impossible. But it happened. Together Rwandans were able to fashion and implement home-grown solutions to their shared problems.

The emphasis on gender equity, on women as visionary leaders, not victims, is also key. Research shows that countries that promote women’s rights and increase their access to education and economic opportunity grow faster, are more peaceful, and have less inequality and less corruption compared to countries that don’t.

Rwanda has many remaining challenges, but it staged one of the most impressive comebacks of modern times. Its leaders, led by President Kagame, rejected the policies of hate and division and retribution, and rebuilt the country from the ashes.

That provides some hope and evidence that Gaza, Ukraine, and other conflict-ravaged countries can too. Thirty years after the genocide, Rwanda is living proof that it is possible.

Professor Margee Ensign is the President of the American University in Bulgaria and author of Rwanda: History and Hope and co-editor of Confronting Genocide in Rwanda.

IPS UN Bureau

 


!function(d,s,id){var js,fjs=d.getElementsByTagName(s)[0],p=/^http:/.test(d.location)?’http’:’https’;if(!d.getElementById(id)){js=d.createElement(s);js.id=id;js.src=p+’://platform.twitter.com/widgets.js’;fjs.parentNode.insertBefore(js,fjs);}}(document, ‘script’, ‘twitter-wjs’);  

Women Affected by ‘Gender-Biased’ Climate Change Deserve Justice

While research into the unequal impacts of climate change on women is growing, more is needed to enable them to realize their rights to climate justice. Researchers argue that women and girls have unequal access to food, water, health, education, and even income, thanks to climate change. This makes them more vulnerable. Pedi Obani, an […]

SAN LOSS ALERT: ROSEN, NATIONAL TRIAL COUNSEL, Encourages Banco Santander, S.A. Investors to Inquire About Securities Class Action Investigation – SAN

NEW YORK, April 10, 2024 (GLOBE NEWSWIRE) —

WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Banco Santander, S.A. (NYSE: SAN) resulting from allegations that Santander may have issued materially misleading business information to the investing public.

SO WHAT: If you purchased Santander securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. The Rosen Law Firm is preparing a class action seeking recovery of investor losses.

WHAT TO DO NEXT: To join the prospective class action, go to https://rosenlegal.com/submit–form/?case_id=22671 or call Phillip Kim, Esq. toll–free at 866–767–3653 or email case@rosenlegal.com for information on the class action.

WHAT IS THIS ABOUT: On February 5, 2024, the Financial Times published an article entitled “Iran used Lloyds and Santander accounts to evade sanctions.” This article stated, in part that “Santander UK provided accounts to British front companies secretly owned by a sanctioned Iranian petrochemicals company based near Buckingham Palace, according to documents seen by the Financial Times.”

On this news, Santander’s American Depositary Shares (“ADSs”) fell $0.24 per ADS, or 5.7%, to close at $3.94 per ADS on February 5, 2024.

WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs’ Bar. Many of the firm’s attorneys have been recognized by Lawdragon and Super Lawyers.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the–rosen–law–firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

———————————————–

Contact Information:

        Laurence Rosen, Esq.
        Phillip Kim, Esq.
        The Rosen Law Firm, P.A.
        275 Madison Avenue, 40th Floor
        New York, NY 10016
        Tel: (212) 686–1060
        Toll Free: (866) 767–3653
        Fax: (212) 202–3827
        case@rosenlegal.com
        www.rosenlegal.com


GLOBENEWSWIRE (Distribution ID 9087753)